OPTR, PWRM, FHN, MBTF, TECD, – CRWEPicks.com Stock News! Optimer Pharmaceuticals, Power3 Medical Products, First Horizon National Corp., MBT Financial Corp. and Tech Data Corporation

signup3m

optr Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR)

A Food and Drug Administration advisory panel will evaluate data on the oral drug, fidaxomicin. The medicine would be Optimer’s first product to reach the market if the FDA gives its approval.

http://pennyomega.com/img/optr_highlight2.jpg

Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). In two Phase 3 trials for the treatment of CDI, fidaxomicin was equally effective in clinical cure when compared to vancomycin, the only FDA approved product for CDI.

Clostridium difficile is a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Illness from the bacterium most commonly affects older adults in hospitals or trin long term care facilities and typically occurs after use of antibiotic medications.

Fidaxomicin, OPTR’s lead product candidate, is a new antibiotic with a novel mechanism of action being developed for the treatment of Clostridium difficile infection or CDI, the most common nosocomial, or hospital acquired, diarrhea.

A Food and Drug Administration advisory panel will evaluate data on the oral drug, fidaxomicin. The medicine would be Optimer’s first product to reach the market if the FDA gives its approval.

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society.

George Farmer, an analyst at Canaccord Adams Inc. in New York, said, anticipating a favorable response from the FDA, that Sales of the drug may reach $250 million by 2016.

Optimer Pharmaceuticals is focused on discovering, developing, and commercializing innovative hospital specialty products that have a positive impact on society. The company focus on medicines that make a significant difference in the lives of patients and reduce the burden of disease.

For more information about this company please visit http://www.optimerpharma.com

****

pwrm1_logo_200x72 Power3 Medical Products, Inc. (PWRM.OB)

Breast cancer is a melanoma in which cells in the breast separate and develop without regulation. Around Eighty-five percent of breast cancer occurances start out within the mammary ducts, though approximately 15% arise within the lobules. Tumors inside the chest have a tendency to develop little by little. By the point a mass might be large enough so that you can feel it, it could have been developing for as long as ten years. However, a few tumors may be aggressive, and increase considerably faster.

PWRM applies proprietary methodology to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro.

BC-SeraPro is a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials.

Globally, the blood industry has experienced strong growth from 2005 through 2010 and this is expected to continue through the forecast period. Growth will be fueled by a variety of factors including aging populations in the U.S., Europe and Japan; ongoing technology advancements/new product introductions; and continued strong promotion of blood donation by collection agencies.

The U.S. blood market was worth $7.8 billion in 2007. It should reach $9.5 million by 2012, a compound annual growth rate (CAGR) of 5.7%.

Global Industry Analysts, Inc. (GIA) announced the release of a comprehensive global report on blood glucose meters and strips markets. The global market for blood glucose meters and strips is forecast to reach US$18 billion by the year 2015.

Worldwide, breast cancer consists 10.4% in all cancer occurrence among the ladies, rendering it the most common form of non-skin cancer in females and the fifth most typical reason for cancer death. In ‘04, breast cancers triggered 519,000 fatalities across the world (7% associated with cancer deaths; practically 1% of all deaths). Breast cancer is roughly a hundred situations more established in females compared to men, despite the fact that males are apt to have poorer successes on account of waiting times in a diagnosis

BC-SeraPro™ is then an ideal diagnostic test to evaluate breast cancer abnormalities found by mammogram or breast examination. The test would distinguish women who should have a biopsy from those who can safely avoid one. BC-SeraPro™ could detect the disease at a point when treatment is more effective, less expensive, or both.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease).

For more information about this company please visit http://www.power3medical.com

****

First Horizon National Corp. (NYSE:FHN), through its principal subsidiary First Tennessee Bank, has agreed to sell First Horizon Insurance Inc.

Through this sale First Horizon continues to refine its focus on regional banking as First Tennessee Bank and capital markets as FTN Financial

****

MBT Financial Corp. (Nasdaq:MBTF) recently reported that it will release its first quarter 2011 results after the close of the market on Tuesday, April 19, 2011.

****

Tech Data Corporation (Nasdaq:TECD), a leading distributor of IT products, recently reported that members of the company’s executive leadership team and employee guests will ring the Closing Bell at the NASDAQ MarketSite on Tuesday, April 5, 2011.

The Closing Bell ceremony follows the company’s Investor Day and will commemorate the 25th anniversary of Tech Data’s initial public offering and listing on NASDAQ in April 1986.

*******************************************
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
*******************************************

business Card 3

******************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer (http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares 144 restricted stocks for IT department services and 2,000,000 shares (free trade) for 12 months of video production from Power 3 Medical Products Inc. (PWRM.OB).

 
Share/Bookmark
 
 
 
 


Latest News